Moreover, loss or inactivating mutations in the FAT1 tumor suppressor gene, which normally inhibits Hippo signaling, led to the enrichment of YAP/TAZ transcription factors on the CDK6 promoter, ultimately causing CDK6 amplification and resistance to CDK4/6is in ER+ breast cancer [80]. This evidence concerns the gene FAT1 and breast cancer.